ArticleAntimicrobial agents and chemotherapy2025
Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors.
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- Current State of the Fight Against Antimicrobial Resistance: What Are the Different Strategies for Tomorrow?Antibiotics (Basel, Switzerland) · 2026Review
- Disarming carbapenemase-producingAntimicrobial agents and chemotherapy · 2026Article
- Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Antibacterial activity of enmetazobactam againstAntimicrobial agents and chemotherapy · 2026Article
- Classification and applicability of new beta-lactamase inhibitors.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Paradoxical carbapenemase activity detected by modified carbapenemase inactivation (mCIM) method inJournal of clinical microbiology · 2025Article
- Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations.Antimicrobial agents and chemotherapy · 2025Article
- Challenges of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Michelle Outeda-García *Microbiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.ORCID 0000-0002-6737-0239
Jorge Arca-Suárez *Microbiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.ORCID 0000-0002-4248-503X
Emilio LenceCentro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Jenaro de la Fuente s/n, Santiago de Compostela, Spain.
Arianna Rodriguez-CoelloMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
Romina MaceirasMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
Tania Blanco-MartinMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
Paula Guijarro-SánchezMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
Lucia Gonzalez-PintoMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
Isaac Alonso-GarciaMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
Andrea García-PoseMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
Andrea MurasMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
Salud Rodriguez-PallaresMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.
Cristina Lasarte-MonterrubioMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.ORCID 0000-0003-3351-2064
Concepción Gonzalez-BelloCentro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Jenaro de la Fuente s/n, Santiago de Compostela, Spain.
Juan Carlos Vázquez-UchaMicrobiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.ORCID 0000-0003-4949-0779
German Bou *Microbiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.ORCID 0000-0001-8837-0062
Alejandro Beceiro *Microbiology department, A Coruna University Hospital (CHUAC), Institute of Biomedical Research of A Coruna (INIBIC), A Coruna, Spain.ORCID 0000-0002-6340-7815
Funding
Axencia Galega de Innovación IN607A 2020/05Axencia Galega de Innovación IN607D 2021/12Axencia Galega de Innovación IN607D 2024/008MEC | Instituto de Salud Carlos III (ISCIII) CB21/13/00055MEC | Instituto de Salud Carlos III (ISCIII) CM23/00095MEC | Instituto de Salud Carlos III (ISCIII) CM23/00104MEC | Instituto de Salud Carlos III (ISCIII) FI23/00074MEC | Instituto de Salud Carlos III (ISCIII) JR21/00026MEC | Instituto de Salud Carlos III (ISCIII) JR23/00036MEC | Instituto de Salud Carlos III (ISCIII) PI20/00686MEC | Instituto de Salud Carlos III (ISCIII) PI20/01212MEC | Instituto de Salud Carlos III (ISCIII) PI21/00704MEC | Instituto de Salud Carlos III (ISCIII) PI22/01212MEC | Instituto de Salud Carlos III (ISCIII) PI23/00851Spanish State Agency of Research PID2022-136963OB-I00/AEI/10.13039/501100011033Xunta de Galicia ED431C 2021/29Xunta de Galicia ED431G 2023/03Xunta de Galicia IN606A 2021/021Xunta de Galicia IN606A 2023/023Xunta de Galicia IN606B-2022/009
Abstract
Carbapenemase OXA-48 and its variants pose a serious threat to the development of effective treatments for bacterial infections. OXA-48-producing Enterobacterales are the most prevalent carbapenemase-producing bacteria in large parts of the world. Although these bacteria exhibit low-level carbapenem resistance
Indexed as
Anti-Bacterial AgentsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-LactamasesAzabicyclo CompoundsBorinic AcidsBoron CompoundsBoronic AcidsCarboxylic AcidsCefepimeCeftazidimeCyclooctanesHeterocyclic Compounds, 1-RingHumansLactamsMeropenemAnti-Bacterial AgentsavibactamAzabicyclo CompoundsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-LactamasesBorinic AcidsBoron CompoundsBoronic AcidscarbapenemaseCarboxylic AcidsCefepimeCeftazidimeCyclooctanesHeterocyclic Compounds, 1-RingLactamsMeropenemnacubactamPiperidinesrelebactamtaniborbactamvaborbactamzidebactam1,6-diazabicyclo[3,2,1]octanesbicyclic boronatescarbapenem resistanceEnterobacteralesOXA-48β-lactamase inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.